These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7625684)

  • 1. Immune responses to pertussis vaccines concurrently administered with viral vaccines.
    Halperin SA; Eastwood BJ; Langley JM
    Ann N Y Acad Sci; 1995 May; 754():89-96. PubMed ID: 7625684
    [No Abstract]   [Full Text] [Related]  

  • 2. [The immunological basis of the administration of DTP-polio vaccine].
    Cohen H
    Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the status of acellular pertussis vaccines in practice.
    Lopez AL; Blumberg DA
    Drugs; 1997 Aug; 54(2):189-96. PubMed ID: 9257078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of adjuvant effect of the pertussis component on IPV DTP-polio vaccine in children.
    Cadoz M; Montagnon B; Yvonnet B; Xueref C; Vincent-Falquet JC; Bandet R; Gibelin N
    Dev Biol Stand; 1986; 65():153-8. PubMed ID: 2881819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal.
    Relyveld E; Oato NH; Guérin N; Coursaget P; Huet M; Gupta RK
    Vaccine; 1991 Nov; 9(11):843-50. PubMed ID: 1759508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA; King J; Law B; Mills E; Willems P
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inactivated poliovirus vaccine on the antibody response to Bordetella pertussis antigens when combined with diphtheria-pertussis-tetanus vaccine.
    Halperin SA; Langley JM; Eastwood BJ
    Clin Infect Dis; 1996 Jan; 22(1):59-62. PubMed ID: 8824967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, immunogenicity and efficacy results of a 2-component DT acellular pertussis paediatric vaccine and its combinations with IPV and HIB antigens.
    Vose JR; Hoffenbach A
    Biologicals; 1999 Jun; 27(2):97-8. PubMed ID: 10600192
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
    Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
    Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a combined DTP-polio vaccine in a reduced schedule.
    Swartz TA; Roumiantzeff M; Peyron L; Stopler T; Drucker J; Epstein I; Leitner L; Goldblum N
    Dev Biol Stand; 1986; 65():159-66. PubMed ID: 2881820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines.
    Baker JD; Halperin SA; Edwards K; Miller B; Decker M; Stephens D
    J Pediatr; 1992 Oct; 121(4):523-7. PubMed ID: 1403383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
    Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
    Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.